BackSummit Therapeutics Overview

Summit Therapeutics Receivables

Summit Therapeutics's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

Summit Therapeutics Receivables History

Loading

Summit Therapeutics vs. peers: Receivables Comparison

Loading

Summit Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Summit Therapeutics (SMMT) FAQ

Summit Therapeutics posts a receivables of $0 as of June 2026. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Summit Therapeutics's receivables was $0. The latest reading is $0 (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Summit Therapeutics's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SMMT's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Summit Therapeutics's other metric pages and overview cover the third.